Incid nc of Abnormal M tabolic parameters and weight gain induced by atypical antipsychotics in elderly patients with dementia

Monica Mathys, Amie Blaszczyk, Anthony Busti

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: To determine if atypical antipsychotic therapy leads to the development of abnormal metabolic parameters and weight gain in elderly patients with dementia. Design: Retrospective chart review. Setting: Veterans Affairs Medical Center. Patients: Veterans 65 years of age or older with the diagnosis of dementia. Main Outcome Measure: The incidence of impaired fasting glucose (> 100 mg/dL) after initiation of atypical antipsychotic therapy. The secondary objectives were to determine the incidence of significant weight gain, worsening of lipid values, new onset of type 2 diabetes mellifus, and metabolic syndrome. Results: After reviewinq 979 charts for inclusion and exclusion criteria, 56 patients were found eligible for the study. More than 50% of patients were excluded because they were lacking baseline or follow-up glucose laboratory results. Ten percent of the study population developed impaired fasting glucose after starting atypical antipsychotic therapy. Overall glucose increased by 9.7 mg/dL from baseline to follow-up. Significant weight gain (≥ 7% of baseline weight) occurred in 8.92% of elderly. However, overall weight decreased by 1.3 kg during the study periods. Patients who developed worsening lipid parameters or were started on lipid-lowering therapy were 14.5% of the study population even though overall lipid levels improved or remained unchanged. Conclusion: Periodic monitoring of glucose should be considered for patients with dementia begun on atypical antipsychotics, although aggressive monitoring may be controversial for end-stage dementia. Overall, weight reduction and improvement in lipid parameters were observed in this study. The common metabolic adverse effects noted frequently with atypical antipsychotics may not be as much of a concern with the elderly population.

Original languageEnglish (US)
Pages (from-to)201-209
Number of pages9
JournalConsultant Pharmacist
Volume24
Issue number3
StatePublished - Mar 1 2009

Fingerprint

Antipsychotic Agents
Weight Gain
Dementia
Lipids
Glucose
Veterans
Fasting
Population
Weights and Measures
Incidence
Therapeutics
Type 2 Diabetes Mellitus
Weight Loss
Outcome Assessment (Health Care)

Keywords

  • Atypical antipsychotic
  • Dementia
  • Elderly
  • Impaired fastinq glucose
  • Metabolic syndrome
  • Weiqht qain

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Incid nc of Abnormal M tabolic parameters and weight gain induced by atypical antipsychotics in elderly patients with dementia. / Mathys, Monica; Blaszczyk, Amie; Busti, Anthony.

In: Consultant Pharmacist, Vol. 24, No. 3, 01.03.2009, p. 201-209.

Research output: Contribution to journalArticle

@article{eb12a8d2f3534000b8ec1f5f7c595b75,
title = "Incid nc of Abnormal M tabolic parameters and weight gain induced by atypical antipsychotics in elderly patients with dementia",
abstract = "Objective: To determine if atypical antipsychotic therapy leads to the development of abnormal metabolic parameters and weight gain in elderly patients with dementia. Design: Retrospective chart review. Setting: Veterans Affairs Medical Center. Patients: Veterans 65 years of age or older with the diagnosis of dementia. Main Outcome Measure: The incidence of impaired fasting glucose (> 100 mg/dL) after initiation of atypical antipsychotic therapy. The secondary objectives were to determine the incidence of significant weight gain, worsening of lipid values, new onset of type 2 diabetes mellifus, and metabolic syndrome. Results: After reviewinq 979 charts for inclusion and exclusion criteria, 56 patients were found eligible for the study. More than 50{\%} of patients were excluded because they were lacking baseline or follow-up glucose laboratory results. Ten percent of the study population developed impaired fasting glucose after starting atypical antipsychotic therapy. Overall glucose increased by 9.7 mg/dL from baseline to follow-up. Significant weight gain (≥ 7{\%} of baseline weight) occurred in 8.92{\%} of elderly. However, overall weight decreased by 1.3 kg during the study periods. Patients who developed worsening lipid parameters or were started on lipid-lowering therapy were 14.5{\%} of the study population even though overall lipid levels improved or remained unchanged. Conclusion: Periodic monitoring of glucose should be considered for patients with dementia begun on atypical antipsychotics, although aggressive monitoring may be controversial for end-stage dementia. Overall, weight reduction and improvement in lipid parameters were observed in this study. The common metabolic adverse effects noted frequently with atypical antipsychotics may not be as much of a concern with the elderly population.",
keywords = "Atypical antipsychotic, Dementia, Elderly, Impaired fastinq glucose, Metabolic syndrome, Weiqht qain",
author = "Monica Mathys and Amie Blaszczyk and Anthony Busti",
year = "2009",
month = "3",
day = "1",
language = "English (US)",
volume = "24",
pages = "201--209",
journal = "The Senior care pharmacist",
issn = "2639-9636",
publisher = "American Society of Consultant Pharmacists",
number = "3",

}

TY - JOUR

T1 - Incid nc of Abnormal M tabolic parameters and weight gain induced by atypical antipsychotics in elderly patients with dementia

AU - Mathys, Monica

AU - Blaszczyk, Amie

AU - Busti, Anthony

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Objective: To determine if atypical antipsychotic therapy leads to the development of abnormal metabolic parameters and weight gain in elderly patients with dementia. Design: Retrospective chart review. Setting: Veterans Affairs Medical Center. Patients: Veterans 65 years of age or older with the diagnosis of dementia. Main Outcome Measure: The incidence of impaired fasting glucose (> 100 mg/dL) after initiation of atypical antipsychotic therapy. The secondary objectives were to determine the incidence of significant weight gain, worsening of lipid values, new onset of type 2 diabetes mellifus, and metabolic syndrome. Results: After reviewinq 979 charts for inclusion and exclusion criteria, 56 patients were found eligible for the study. More than 50% of patients were excluded because they were lacking baseline or follow-up glucose laboratory results. Ten percent of the study population developed impaired fasting glucose after starting atypical antipsychotic therapy. Overall glucose increased by 9.7 mg/dL from baseline to follow-up. Significant weight gain (≥ 7% of baseline weight) occurred in 8.92% of elderly. However, overall weight decreased by 1.3 kg during the study periods. Patients who developed worsening lipid parameters or were started on lipid-lowering therapy were 14.5% of the study population even though overall lipid levels improved or remained unchanged. Conclusion: Periodic monitoring of glucose should be considered for patients with dementia begun on atypical antipsychotics, although aggressive monitoring may be controversial for end-stage dementia. Overall, weight reduction and improvement in lipid parameters were observed in this study. The common metabolic adverse effects noted frequently with atypical antipsychotics may not be as much of a concern with the elderly population.

AB - Objective: To determine if atypical antipsychotic therapy leads to the development of abnormal metabolic parameters and weight gain in elderly patients with dementia. Design: Retrospective chart review. Setting: Veterans Affairs Medical Center. Patients: Veterans 65 years of age or older with the diagnosis of dementia. Main Outcome Measure: The incidence of impaired fasting glucose (> 100 mg/dL) after initiation of atypical antipsychotic therapy. The secondary objectives were to determine the incidence of significant weight gain, worsening of lipid values, new onset of type 2 diabetes mellifus, and metabolic syndrome. Results: After reviewinq 979 charts for inclusion and exclusion criteria, 56 patients were found eligible for the study. More than 50% of patients were excluded because they were lacking baseline or follow-up glucose laboratory results. Ten percent of the study population developed impaired fasting glucose after starting atypical antipsychotic therapy. Overall glucose increased by 9.7 mg/dL from baseline to follow-up. Significant weight gain (≥ 7% of baseline weight) occurred in 8.92% of elderly. However, overall weight decreased by 1.3 kg during the study periods. Patients who developed worsening lipid parameters or were started on lipid-lowering therapy were 14.5% of the study population even though overall lipid levels improved or remained unchanged. Conclusion: Periodic monitoring of glucose should be considered for patients with dementia begun on atypical antipsychotics, although aggressive monitoring may be controversial for end-stage dementia. Overall, weight reduction and improvement in lipid parameters were observed in this study. The common metabolic adverse effects noted frequently with atypical antipsychotics may not be as much of a concern with the elderly population.

KW - Atypical antipsychotic

KW - Dementia

KW - Elderly

KW - Impaired fastinq glucose

KW - Metabolic syndrome

KW - Weiqht qain

UR - http://www.scopus.com/inward/record.url?scp=62549086012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62549086012&partnerID=8YFLogxK

M3 - Article

C2 - 19555135

AN - SCOPUS:62549086012

VL - 24

SP - 201

EP - 209

JO - The Senior care pharmacist

JF - The Senior care pharmacist

SN - 2639-9636

IS - 3

ER -